296 related articles for article (PubMed ID: 30605863)
1. Metabolic pathways of L-arginine and therapeutic consequences in tumors.
Szefel J; Danielak A; Kruszewski WJ
Adv Med Sci; 2019 Mar; 64(1):104-110. PubMed ID: 30605863
[TBL] [Abstract][Full Text] [Related]
2. The effect of l-arginine supplementation and surgical trauma on the frequency of myeloid-derived suppressor cells and T lymphocytes in tumour and blood of colorectal cancer patients.
Szefel J; Ślebioda T; Walczak J; Kruszewski WJ; Szajewski M; Ciesielski M; Stanisławowski M; Buczek T; Małgorzewicz S; Owczarzak A; Aleksandrowicz-Wrona E; Krzykowski G
Adv Med Sci; 2022 Mar; 67(1):66-78. PubMed ID: 34995935
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
[TBL] [Abstract][Full Text] [Related]
4. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.
Najac C; Chaumeil MM; Kohanbash G; Guglielmetti C; Gordon JW; Okada H; Ronen SM
Sci Rep; 2016 Aug; 6():31397. PubMed ID: 27507680
[TBL] [Abstract][Full Text] [Related]
5. Does placental MDSC-mediated modulation of arginine levels help protect the foetus from auxotrophic pathogens?
Ismail AQT
J Matern Fetal Neonatal Med; 2018 Jun; 31(12):1667-1669. PubMed ID: 28462680
[TBL] [Abstract][Full Text] [Related]
6. Myeloid Cell-Derived Arginase in Cancer Immune Response.
Grzywa TM; Sosnowska A; Matryba P; Rydzynska Z; Jasinski M; Nowis D; Golab J
Front Immunol; 2020; 11():938. PubMed ID: 32499785
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion.
Leonard W; Dufait I; Schwarze JK; Law K; Engels B; Jiang H; Van den Berge D; Gevaert T; Storme G; Verovski V; Breckpot K; De Ridder M
Radiother Oncol; 2016 May; 119(2):291-9. PubMed ID: 26874542
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis and current strategies of therapeutic arginine depletion for cancer.
Fultang L; Vardon A; De Santo C; Mussai F
Int J Cancer; 2016 Aug; 139(3):501-9. PubMed ID: 26913960
[TBL] [Abstract][Full Text] [Related]
9. L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.
Cao Y; Feng Y; Zhang Y; Zhu X; Jin F
BMC Cancer; 2016 Jun; 16():343. PubMed ID: 27246354
[TBL] [Abstract][Full Text] [Related]
10. L-arginine metabolism in myeloid cells controls T-lymphocyte functions.
Bronte V; Serafini P; Mazzoni A; Segal DM; Zanovello P
Trends Immunol; 2003 Jun; 24(6):302-6. PubMed ID: 12810105
[TBL] [Abstract][Full Text] [Related]
11. Targeting arginine metabolism pathway to treat arginine-dependent cancers.
Qiu F; Huang J; Sui M
Cancer Lett; 2015 Aug; 364(1):1-7. PubMed ID: 25917076
[TBL] [Abstract][Full Text] [Related]
12. mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors.
Wu T; Zhao Y; Wang H; Li Y; Shao L; Wang R; Lu J; Yang Z; Wang J; Zhao Y
Sci Rep; 2016 Feb; 6():20250. PubMed ID: 26833095
[TBL] [Abstract][Full Text] [Related]
13. Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity.
Cimen Bozkus C; Elzey BD; Crist SA; Ellies LG; Ratliff TL
J Immunol; 2015 Dec; 195(11):5237-50. PubMed ID: 26491198
[TBL] [Abstract][Full Text] [Related]
14. A Dynamic Metabolic Flux Analysis of Myeloid-Derived Suppressor Cells Confirms Immunosuppression-Related Metabolic Plasticity.
Goffaux G; Hammami I; Jolicoeur M
Sci Rep; 2017 Aug; 7(1):9850. PubMed ID: 28852166
[TBL] [Abstract][Full Text] [Related]
15. l-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice.
Cao Y; Wang Q; Du Y; Liu F; Zhang Y; Feng Y; Jin F
Int Immunopharmacol; 2016 Jun; 35():7-14. PubMed ID: 27003114
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent.
Nasreddine G; El-Sibai M; Abi-Habib RJ
Invest New Drugs; 2020 Feb; 38(1):10-19. PubMed ID: 30887252
[TBL] [Abstract][Full Text] [Related]
17. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-β/β-catenin pathway.
Kang X; Zhang X; Liu Z; Xu H; Wang T; He L; Zhao A
Mol Hum Reprod; 2016 Jul; 22(7):499-511. PubMed ID: 27016139
[TBL] [Abstract][Full Text] [Related]
18. Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer.
Wang J; Yang L; Yu L; Wang YY; Chen R; Qian J; Hong ZP; Su XS
Oncotarget; 2017 Mar; 8(10):17050-17058. PubMed ID: 28178645
[TBL] [Abstract][Full Text] [Related]
19. Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma.
Tate DJ; Vonderhaar DJ; Caldas YA; Metoyer T; Patterson JR; Aviles DH; Zea AH
J Hematol Oncol; 2008 Sep; 1():14. PubMed ID: 18817562
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
